TREATMENT AND DIAGNOSIS
Diagnosing myelodysplastic syndromes can be difficult. Your doctor first needs to
rule out any other blood disorders before a diagnosis can be made. DACOGEN®
(decitabine) for Injection not only treats the symptoms of myelodysplastic syndromes,
it treats the underlying disease by working on the DNA. Patients responding to DACOGEN
may see an improvement in their blood cell counts, which could mean fewer blood
transfusions.
Learn more about the treatment and diagnosis of MDS:
DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS),
including previously treated and untreated, de novo, and secondary MDS of all FAB
subtypes (RA, RARS, RAEB, RAEB-t, CMML) and Intermediate-1, Intermediate-2, and
High-Risk IPSS groups.
DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing
potential should be advised to avoid becoming pregnant while using DACOGEN. Men
should be advised not to father a child while receiving treatment with DACOGEN,
and for 2 months afterwards. The most commonly occurring adverse reactions include
neutropenia, thrombocytopenia, anemia, fatigue, pyrexia, nausea, cough, petechiae,
constipation, diarrhea, and hyperglycemia.
DACOGEN is available by prescription only. Please see the important product information
for DACOGEN for more information. This site does not contain everything that is
known about DACOGEN. If you would like to know more, talk to your healthcare professional.